Stocktoria
Galmed Pharmaceuticals Ltd. GLMD
Galmed Pharmaceuticals Ltd. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $2.0M | $1.1M | $467,000 |
| R&D expense | $4.9M | $3.0M | $3.6M | $13.0M | $27.2M | $26.1M | $18.2M | $8.3M | $9.7M | $14.3M |
| Operating income | — | — | — | — | — | -$30.2M | -$22.4M | -$10.7M | -$12.4M | — |
| Income tax | $0 | — | — | — | — | $0 | $0 | $75,000 | $0 | $106,000 |
| Net income | -$10.3M | -$7.5M | -$6.9M | -$17.9M | -$32.5M | -$28.8M | -$20.5M | — | — | — |
| EPS (diluted) | $2.39 | $8.08 | $30.00 | $127.80 | $19.80 | — | — | — | — | — |
| Operating cash flow | -$6.3M | -$5.9M | -$6.1M | -$18.5M | -$32.9M | -$26.3M | -$14.9M | -$9.0M | -$12.1M | -$12.1M |
| Free cash flow | — | — | — | -$18.5M | -$32.9M | -$26.3M | -$14.9M | -$9.1M | -$12.1M | -$12.1M |
| Cash & equivalents | $4.0M | $4.7M | $2.9M | $2.0M | $2.9M | $6.9M | $15.9M | $24.2M | $13.0M | $3.1M |
| Total assets | $18.6M | $18.5M | $16.6M | $16.6M | $36.6M | $52.4M | $77.1M | $90.6M | $19.6M | $16.4M |
| Shareholders' equity | $15.8M | $16.3M | $13.9M | $13.4M | $30.5M | $44.2M | $69.9M | $87.9M | $15.8M | $11.1M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | — | -100.0% | +87.8% | +132.3% | — |
| EPS growth | -70.4% | -73.1% | -76.5% | +545.5% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.